Targeting TIGIT for cancer immunotherapy: recent advances and future directions

被引：0

作者：

Peng Zhang

Xinyuan Liu

Zhuoyu Gu

Zhongxing Jiang

Song Zhao

Yongping Song

Jifeng Yu

机构：

[1] the First Affiliated Hospital of Zhengzhou University,Department of Thoracic Surgery

[2] Henan Medical Key Laboratory of Thoracic Oncology,Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences

[3] Henan University,Department of Hematology

[4] the First Affiliated Hospital of Zhengzhou University,Henan International Joint Laboratory of Nuclear Protein Gene Regulation

[5] Henan University College of Medicine,undefined

来源：

Biomarker Research | / 12卷

关键词：

TIGIT; Target immunotherapy; Immune checkpoint pathway; cancer immunotherapy; Clinical trial;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+ T cells, CD8+ T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes (TILs). TIGIT has been associated with NK cell exhaustion in vivo and in individuals with various cancers. It not only modulates NK cell survival but also mediates T cell exhaustion. As the primary ligand of TIGIT in humans, CD155 may be the main target for immunotherapy due to its interaction with TIGIT. It has been found that the anti-programmed cell death protein 1 (PD-1) treatment response in cancer immunotherapy is correlated with CD155 but not TIGIT. Anti-TIGIT alone and in combination with anti-PD-1 agents have been tested for cancer immunotherapy. Although two clinical studies on advanced lung cancer had positive results, the TIGIT-targeted antibody, tiragolumab, recently failed in two new trials. In this review, we highlight the current developments on TIGIT for cancer immunotherapy and discuss the characteristics and functions of TIGIT.

引用

共 1976 条

[51]

Wu L(2018)TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma Blood. 132 1689-50

[52]

Feng J(2018)Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade Blood. 132 1675-526.e9

[53]

Zhang Y(2020)Modulation of regulatory T cell function and stability by co-inhibitory receptors Nat Rev Immunol. 20 680-11013

[54]

Luft AV(2014)Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses Immunity. 40 569-2608

[55]

Zhou J(2022)Peritumoral TIGIT(+)CD20(+) B cell infiltration indicates poor prognosis but favorable adjuvant chemotherapeutic response in gastric cancer Int Immunopharmacol. 108 108735-120

[56]

Ma Z(2021)Implication of TIGIT(+) human memory B cells in immune regulation Nat Commun. 12 1534-571

[57]

Lu Y(2018)Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivo by suppressing the function of NK and CD8(+) T cells Front Immunol. 9 2821-3998

[58]

Hu C(2019)A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function J Immunother Cancer. 7 243-183

[59]

Shi Y(2019)Clinical significance of CD8(+) T cell immunoreceptor with Ig and ITIM domains(+) in locally advanced gastric cancer treated with SOX regimen after D2 gastrectomy Oncoimmunology. 8 e1593807-438

[60]

Baudelet C(2022)Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer Br J Cancer. 127 1026-3013

← 1 2 3 4 5 6 7 8 9 10 →